Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10188680-B2
Publication Date
2019-01-29
Expiration Date
Abstract
Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.
Core Innovation
The invention provides a composition comprising a yeast cell wall particle and a tumor lysate, in which about 200 g to about 500 g tumor lysate is loaded within about 10^9 yeast cell wall particles. The resulting material is a tumor-lysate-loaded yeast cell wall particle.
The invention further involves dendritic cells and the phagocytosis of the tumor lysate loaded particle by the dendritic cell. Through the use of dendritic cells containing phagocytosed tumor-lysate-loaded particles, the invention is directed to anti-tumor immunity via Major Histocompatibility Complex class I antigen presentation and CD8+ T cells.
The disclosed approach includes loading the tumor lysate within yeast cell wall particles and freeze-drying the resulting material, optionally with resuspending and freeze-drying cycles to trap anhydrous lysate. The tumor-lysate-loaded particles are then incubated with dendritic cells to induce phagocytosis, followed by administration of the resulting dendritic-cell vaccine for cancer treatment, including ocular melanoma.
Claims Coverage
The independent claim coverage includes a composition claim and a method claim. Across the independent claim set, the core inventive features are the quantified tumor-lysate loading into yeast cell wall particles and the incorporation of dendritic cells with phagocytosis to drive MHC class I antigen presentation and CD8+ T-cell responses.
Yeast cell wall particle loaded with tumor lysate at defined loading levels
A composition comprising a yeast cell wall particle and a tumor lysate, wherein about 200 g to about 500 g tumor lysate is loaded within about 10^9 yeast cell wall particles.
Tumor lysate loaded yeast cell wall particle and dendritic-cell phagocytosis for anti-tumor immunity
A cancer vaccine concept including dendritic cells wherein the tumor lysate loaded particle is phagocytosed by the dendritic cell to drive anti-tumor immunity via Major Histocompatibility Complex class I antigen presentation and CD8+ T cells.
Overall, the independent claim coverage focuses on a composition with defined amounts of tumor lysate loaded into a defined number of yeast cell wall particles and using dendritic cells that phagocytose the tumor-lysate-loaded particles to elicit anti-tumor immunity through MHC class I antigen presentation involving CD8+ T cells.
Stated Advantages
Anti-tumor immunity is driven via Major Histocompatibility Complex class I antigen presentation.
The approach is reported to induce CD8+ T-cell responses.
Documented Applications
Cancer treatment using the dendritic-cell vaccine, including ocular melanoma.
Interested in licensing this patent?